CombinatoRx (CRXX) Posts Q3 Loss, Better Y/Y
More News related to CRXX
- CombinatoRx Oncology Programs to Be Highlighted at ASH 2009
- CombinatoRx, Inc. (CRXX) and Neruomed Pharma Receive U.S. FDA Letter Regarding NDA for Exalgo
- FDA Extends NDA Review for Exalgo(TM) Extended-Release Tablets
- Unusual 11 Mid-Day Movers 11/16: SPEX, NLST, DRAM, XJT Higher; PARD, CRXX, CAEI, CHIO Lower
- Morning Movers 11/16: SPEX, NLST, XJT, NABI, KHD, IBKC, SPA Higher; PARD, CRXX, CAEI Lower
More News related to Earnings
- Notable Mergers and Acquisitions of the Day 11/25: PEET/DDRX/GMCR, ERIC, URX
- Morning Movers 11/25: RTK, QADI, GGR, HEV, CAEI Higher; BNHN, DRAM, CWTR, CONN Lower
- After-Hours Movers 11/24: QADI, JCG, ASYS Higher; DRAM, CWTR Lower
- Trading Radar for 11/25: Deere & Co. (DE), Tiffany & Co. (TIF), Conn's (CONN) Report
- Afternoon ETF Check: SMH Up; XLF, TAN, EWJ Down
CombinatoRx, Incorporated (NASDAQ: CRXX) reports Q3 loss of $0.24, compared to ($0.45) in the same quarter last year. Revenue for the quarter was $2.7 million, versus $3.0 million in Q308.
Related Categories
EarningsStocks Mentioned
-0.02Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
